Nisha Pandey

Alzheimer's Drug Leqembi Helps Over 75% Of Patients Remain Stable Or Improve: Real-World Study

Alzheimer's Drug Leqembi May Help Over 75% of Patients Remain Stable Or Improve: Real-World Study

A study suggests that <span>Leqembi</span> (<span>lecanemab</span>), one of the first amyloid-targeted treatments for <span><a href="https://www.healthandme.com/health/alzheimers-disease">Alzheimer's disease</a></span>, may help people maintain their cognitive abilities for longer than previously thought. 

Researchers reported at the Alzheimer's Association International Conference (AAIC) 2026 that more than 75% of patients with early Alzheimer's disease remained stable, while nearly 7% showed improvement after receiving Leqembi for an average period of 17 months. 

<h2>Leqembi's Effect On Alzheimer's Patients </h2>

The findings come from the LEADER study, an ongoing observational study that evaluates the effectiveness of Leqembi outside the controlled environment of clinical trials. 

The analysis included people with early <a href="https://www.healthandme.com/health-news/radio-broadcaster-paul-gambaccini-reveals-alzheimers-disease-diagnosis-article-155043133" data-type="tilCustomLink">Alzheimer's disease</a>, including those with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia. 

<ul><li>75.9% of patients remained clinically stable</li><li>6.6% improved by one disease stage</li><li>Nearly 83% were either stable or improved during treatment over an average follow-up of 17 months. </li></ul>

The study is based on how the drug performs in routine medical practice, offering insight into its real-world effectiveness.

Also read: <a href="https://www.healthandme.com/health-news/captain-sully-sullenberger-miracle-on-the-hudson-pilot-reveals-early-stage-alzheimers-diagnosis-article-155101166" data-type="tilCustomLink">Captain ‘Sully’ Sullenberger, ‘Miracle On The Hudson’ Pilot, Reveals Early-Stage Alzheimer’s Diagnosis</a> 

<h2>Success In Earlier Clinical Trial </h2>

<a href="https://www.healthandme.com/health-wellness/challenge-your-brain-to-keep-it-young-new-study-says-learning-another-language-can-help-article-154975699" data-type="tilCustomLink">Leqembi</a> received approval in the US after the landmark CLARITY AD Phase 3 trial, which showed the drug slowed cognitive decline by 27% over 18 months compared with placebo in people with early Alzheimer's disease. 

The drug clears amyloid-beta plaques, one of the hallmarks of Alzheimer's disease. Researchers believe that reducing amyloids may control the progression of the disease when treatment begins early. 

Commenting on the new findings, Dr. Michael Irizarry, Deputy Chief Clinical Officer and Senior Vice President at Eisai Inc., said: "These real-world data reinforce the meaningful impact that early diagnosis and treatment with LEQEMBI can have for people living with early Alzheimer's disease." 

The company said the results provide encouraging evidence that the benefits observed in clinical trials are translating into everyday clinical practice.

Also read: <a href="https://www.healthandme.com/health-news/whos-new-dementia-guidelines-prioritize-healthy-habits-warn-against-supplements-article-155105783" data-type="tilCustomLink">WHO's New Dementia Guidelines Prioritize Healthy Habits, Warn Against Supplements</a>  

<h2>Careful Monitoring Still Needed </h2>

Despite the encouraging results, experts say that Leqembi is not appropriate for everyone with Alzheimer's disease. The treatment is suitable for people in the early stages of Alzheimer's disease with confirmed <a href="https://www.healthandme.com/health-news/your-country-may-influence-your-dementia-risk-more-than-you-think-study-suggests-article-155095835" data-type="tilCustomLink">amyloid pathology</a>. 

Patients receiving Leqembi require regular monitoring because the drug can cause amyloid-related imaging abnormalities (ARIA), which may involve <a href="https://www.healthandme.com/health-news/new-blood-test-may-predict-alzheimers-symptoms-at-least-4-years-in-advance-study-article-154946490" data-type="tilCustomLink">brain swelling</a> or bleeding. 

While many cases are asymptomatic, some can be serious, making MRI monitor an important part of treatment. 

<h2>Why <span rel="noindex">Amyloid</span> Clearance Matters? </h2>

WHY TRUMP REFUSES TO AGE?

For years, amyloid plaques have been at the center of Alzheimer’s research. These protein clumps build up between neurons and are believed to interfere with communication and trigger inflammation, eventually killing brain cells. 

While there’s still debate over whether amyloid is a cause or symptom of Alzheimer’s, clearing these plaques remains one of the leading therapeutic targets. 

The latest real-world evidence presented at AAIC 2026 strengthens confidence in Leqembi as a treatment that may help slow the progression of early Alzheimer's disease. 

While the therapy does not reverse the condition or cure <a href="https://www.healthandme.com/health-news/cannabis-based-treatment-shows-promise-in-easing-agitation-in-dementia-new-clinical-trial-article-155108875" data-type="tilCustomLink">dementia</a>, keeping patients clinically stable for longer could translate into more time with preserved independence and daily functioning.

Health Conditions A-Z

health

alzheimers-drug-leqembi-may-help-over-75-of-patients-remain-stable-or-improve-real-world-study

Alzheimer's Disease

Leqembi

lecanemab

alzheimers research

alzheimers leqembi

amyloid

football-legend-kevin-keegan-dies-at-75-after-battle-with-stage-4-stomach-cancer

Football Legend Kevin Keegan Dies At 75 After Battle With Stage 4 Stomach Cancer

high-risk-pregnancy-recognizing-the-warning-signs-before-they-become-emergencies

High-Risk Pregnancy: Recognizing The Warning Signs Before They Become Emergencies

coffee-is-good-for-the-heart-but-your-choice-of-brew-may-raise-bad-cholesterol-american-heart-association

Coffee Is Good For The Heart, But Your Choice Of Brew May Raise Bad Cholesterol: American Heart Association

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

A study suggests that Leqembi (lecanemab), one of the first amyloid-targeted treatments for Alzheimer's disease, may help people maintain their cognitive abilities for longer than previously thought. Researchers reported at the Alzheimer's Association International Conference (AAIC) 2026 that more than 75% of patients with early Alzheimer's disease remained stable, while nearly 7% showed improvement after receiving Leqembi for an average period of 17 months. Leqembi's Effect On Alzheimer's Patients The findings come from the LEADER study, an ongoing observational study that evaluates the effectiveness of Leqembi outside the controlled environment of clinical trials. The analysis included people with early Alzheimer's disease, including those with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia. According  to researchers: 75.9% of patients remained clinically stable6.6% improved by one disease stageNearly 83% were either stable or improved during treatment over an average follow-up of 17 months. The study is based on how the drug performs in routine medical practice, offering insight into its real-world effectiveness.Also read: Captain ‘Sully’ Sullenberger, ‘Miracle On The Hudson’ Pilot, Reveals Early-Stage Alzheimer’s Diagnosis Success In Earlier Clinical Trial Leqembi received approval in the US after the landmark CLARITY AD Phase 3 trial, which showed the drug slowed cognitive decline by 27% over 18 months compared with placebo in people with early Alzheimer's disease. The drug clears amyloid-beta plaques, one of the hallmarks of Alzheimer's disease. Researchers believe that reducing amyloids may control the progression of the disease when treatment begins early. Commenting on the new findings, Dr. Michael Irizarry, Deputy Chief Clinical Officer and Senior Vice President at Eisai Inc., said: "These real-world data reinforce the meaningful impact that early diagnosis and treatment with LEQEMBI can have for people living with early Alzheimer's disease." The company said the results provide encouraging evidence that the benefits observed in clinical trials are translating into everyday clinical practice.Also read: WHO's New Dementia Guidelines Prioritize Healthy Habits, Warn Against Supplements  Careful Monitoring Still Needed Despite the encouraging results, experts say that Leqembi is not appropriate for everyone with Alzheimer's disease. The treatment is suitable for people in the early stages of Alzheimer's disease with confirmed amyloid pathology. Patients receiving Leqembi require regular monitoring because the drug can cause amyloid-related imaging abnormalities (ARIA), which may involve brain swelling or bleeding. While many cases are asymptomatic, some can be serious, making MRI monitor an important part of treatment. Why Amyloid Clearance Matters?                For years, amyloid plaques have been at the center of Alzheimer’s research. These protein clumps build up between neurons and are believed to interfere with communication and trigger inflammation, eventually killing brain cells. While there’s still debate over whether amyloid is a cause or symptom of Alzheimer’s, clearing these plaques remains one of the leading therapeutic targets. The latest real-world evidence presented at AAIC 2026 strengthens confidence in Leqembi as a treatment that may help slow the progression of early Alzheimer's disease. While the therapy does not reverse the condition or cure dementia, keeping patients clinically stable for longer could translate into more time with preserved independence and daily functioning.

alzheimer's drug leqembi may help over 75% of patients remain stable or improve: real-world study

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Alzheimer's Drug Leqembi Helps Over 75% Of Patients Remain Stable Or Improve: Real-World Study

Football Legend Kevin Keegan Dies At 75 After Battle With Stage 4 Stomach Cancer

Ebola Outbreak: Confirmed Cases Hit 2,344, Deaths Rise To 930

Cervical Cancer Cases In India Drop 37% Over A Decade, Highlighting Impact Of Screening & HPV Vaccination

Health Conditions A-Z

Football Legend Kevin Keegan Dies At 75 After Battle With Stage 4 Stomach Cancer

High-Risk Pregnancy: Recognizing The Warning Signs Before They Become Emergencies

Coffee Is Good For The Heart, But Your Choice Of Brew May Raise Bad Cholesterol: American Heart Association